Association of Diabetes Care & Education Specialists

News & Publications

New Position Statement Advocates for Educator Involvement in Formulary/Medical Device Discussions

Oct 06, 2017

Developed by AADE’s Professional Practice Committee, a new AADE position statement makes the case that diabetes educators should, at a minimum, be included as expert consultants for decisions regarding diabetes medication formularies and medical devices.

The position statement differentiates between the types of formularies, discusses their implications and the potential barriers caused by formulary changes for people with diabetes, and outlines the overarching goal for establishing a role for diabetes educators within diabetes formulary and medical device selection and implementation processes.

Read this position statement.

Advice from AADE Director of Accreditation Jodi Lavin-Tompkins, MSN, RN, BC-ADM, CDE, who in a previous role served on her health system’s Endocrine Advisory Committee to the P&T Committee:

  • Determine which departments or people in your organization have the most influence in formulary decisions and work to get in front of them.
    • Give suggestions in a non-adversarial way. Here are a few sample conversation starters:
    • “I am seeing a lot of people with diabetes using X device, and they are not reaching their A1C goals because they have difficulty with X. There is an easier device that would increase success and here is why…but it is not yet on formulary.”
    • “I am seeing really good results with X device, and I am wondering if you would give consideration to removing the requirement for prior authorization? The people with diabetes I work with really like it, and it’s helping them to be more successful with their insulin regimen.”
    • “Many of the people with diabetes I work with are stopping X medication because they don’t tolerate it, but they are not telling their provider until they see them three to six months later. When they have access to the extended release formulation, they tolerate the medication better and are able to continue taking it, but that formulation has limited coverage. For these reasons, could you consider covering the extended release formulation when you next review this class of medication?”
  • Even if you advocate for a medication or device, and it’s not included in the formulary after your discussions, it’s not necessarily a complete loss. You have planted a seed for potential coverage in the future.

For more on diabetes educators and formularies, take a look at Jennifer Clements’, PharmD, BCPS, CDE, BCACP blog post.

In This Section

News & Publications